Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)

Group 1 - Merck & Co., Inc. acquired Prometheus Biosciences for $11 billion, enhancing its pipeline amid high demand [1] - The investment group "Value In Corporate Events" focuses on identifying opportunities in major corporate events such as IPOs, M&A, and earnings reports [1] - The service covers approximately 10 major events monthly, aiming to find the best investment opportunities [1]